Summary by Futu AI
On February 29, 2024, Ginkgo Bioworks Holdings, Inc., a Delaware-based company specializing in cell programming and biosecurity, reported its financial results for the fourth quarter of 2023 and the full year ended December 31, 2023. The company, which trades under the symbol DNA on the NYSE, announced a total revenue of $251 million for 2023, with $139 million generated from Cell Engineering services, marking a 31% growth over the previous year. The addition of 78 new Cell Programs in 2023 represented a 32% increase, with significant expansion in the biopharma sector through partnerships with companies like Boehringer Ingelheim, Merck, Novo Nordisk, and Pfizer. Ginkgo's year-end cash balance stood at nearly $950 million, providing a substantial runway as the company aims for profitability and benefits from improved platform efficiency. The Biosecurity...Show More